Lung Transplant Recipient
7
3
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
14.3%
1 terminated out of 7 trials
50.0%
-36.5% vs benchmark
29%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection
Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients